Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00445666 |
RATIONALE: Biological therapies, such as cellular adoptive immunotherapy using tumor-infiltrating lymphocytes, may stimulate the immune system in different ways and stop cancer cells from growing.
PURPOSE: This phase I trial is studying the side effects and how well tumor-infiltrating lymphocytes work in treating patients with persistent or recurrent B-cell non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, or multiple myeloma after a previous donor stem cell transplant.
Condition | Intervention | Phase |
---|---|---|
Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm |
Drug: therapeutic tumor infiltrating lymphocytes Procedure: biopsy Procedure: conventional surgery Procedure: cytogenetic analysis Procedure: flow cytometry Procedure: fluorescence in situ hybridization Procedure: gene expression profiling Procedure: graft-versus-tumor induction therapy Procedure: immunoenzyme technique Procedure: immunohistochemistry staining method Procedure: immunologic technique Procedure: laboratory biomarker analysis Procedure: polymerase chain reaction |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation With Costimulated, Tumor-Derived Lymphocytes |
Estimated Enrollment: | 36 |
Study Start Date: | August 2007 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a pilot study.
Patients undergo apheresis to collect peripheral blood mononuclear cells (PBMCs). Patients then undergo surgical resection of accessible tumor. Tumor-infiltrating T lymphocytes (TILs) are isolated from tumor tissue, costimulated with PBMCs, and expanded ex vivo to generate tumor-derived lymphocytes (TDLs). Beginning at least 24 days after surgery and within 7 days after tumor assessment, patients receive an infusion of TDL IV in the absence of disease progression or unacceptable toxicity.
Patients undergo blood, bone marrow, and tissue collection periodically during study for correlative studies, including the following: phenotypic and functional characterization of residual tumor and TDL by immunohistochemistry and fluorescent in situ hybridization; identification of prognostic markers of clinical outcome (i.e., HLA-A, -B, and -C; HLA-DR, Fas ligand, CD80, and CD86) by flow cytometry; in vitro assessment of tumor-reactive, selectively expanded T-cell clones by gene expression profiling; and evaluation of immune response by tumor-specific cytotoxicity assays (immunoenzyme techniques) and DNA sequencing for recombinant graft-versus-tumor antigens. Chimerism is assessed with a polymerase chain reaction-based assay and cytogenetics.
After completion of study therapy, patients are followed periodically for at least 5 years.
PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed B-cell non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma chronic lymphocytic leukemia, or multiple myeloma
Underwent prior allogeneic hematopoietic stem cell transplantation (alloHSCT) and failed to respond to the following:
No active leptomeningeal involvement with malignancy
PATIENT CHARACTERISTICS:
PT and PTT normal (or demonstrably not related to coagulopathy)
PRIOR CONCURRENT THERAPY:
United States, Maryland | |
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office | Recruiting |
Bethesda, Maryland, United States, 20892-1182 | |
Contact: Clinical Trials Office - Warren Grant Magnusen Clinical Center 888-NCI-1937 |
Principal Investigator: | Michael R. Bishop, MD | National Cancer Institute (NCI) |
Study ID Numbers: | CDR0000532130, NCI-07-C-0064 |
Study First Received: | March 7, 2007 |
Last Updated: | December 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00445666 |
Health Authority: | Unspecified |
recurrent small lymphocytic lymphoma splenic marginal zone lymphoma extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue nodal marginal zone B-cell lymphoma recurrent mantle cell lymphoma recurrent adult diffuse large cell lymphoma recurrent adult Burkitt lymphoma B-cell chronic lymphocytic leukemia refractory chronic lymphocytic leukemia recurrent grade 1 follicular lymphoma recurrent grade 2 follicular lymphoma |
recurrent grade 3 follicular lymphoma recurrent adult lymphoblastic lymphoma recurrent adult immunoblastic large cell lymphoma recurrent marginal zone lymphoma recurrent adult diffuse mixed cell lymphoma recurrent adult diffuse small cleaved cell lymphoma stage I multiple myeloma stage II multiple myeloma stage III multiple myeloma refractory multiple myeloma recurrent adult Hodgkin lymphoma |
Leukemia, Lymphoid Hodgkin's disease Blood Protein Disorders Hodgkin lymphoma, adult Lymphoma, Mantle-Cell Lymphoma, small cleaved-cell, diffuse Lymphoma, Follicular Lymphoma, B-Cell, Marginal Zone Paraproteinemias Hemostatic Disorders Lymphoma, large-cell, immunoblastic Lymphoma, large-cell Lymphoma, B-Cell Burkitt's lymphoma Leukemia |
Hemorrhagic Disorders Multiple myeloma Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Large-Cell, Immunoblastic Hodgkin Disease Lymphoma Chronic lymphocytic leukemia Lymphoma, Large B-Cell, Diffuse Immunoproliferative Disorders Hematologic Diseases Leukemia, B-cell, chronic Blood Coagulation Disorders Vascular Diseases Lymphoblastic lymphoma Mantle cell lymphoma |
Neoplasms Neoplasms by Histologic Type Immune System Diseases Cardiovascular Diseases |